EllisLab_

👏🏼👏🏼👏🏼👏🏼

🧬 We're Hiring: The Shrestha Lab (@raunakms) at CPDR is looking for motivated #PostDoc to work at the intersection of #ComputationalBiology & #MachineLearning #AI Fresh PhD graduates (or defending PhD soon) are highly encouraged to apply 📌 Apply here: iaaxmg.fa.ocs.oraclegovcloud.com/hcmUI/Candidat…

🧬 We're Hiring: The Shrestha Lab at @CPDR_Labs is looking for motivated #PostDoc to work at the intersection of #ComputationalBiology & #MachineLearning #AI Fresh PhD graduates (or defending PhD soon) are highly encouraged to apply 📌 Apply here: iaaxmg.fa.ocs.oraclegovcloud.com/hcmUI/Candidat…

Online Now: Gregory J. Hannon (1964–2026) dlvr.it/TT3vmB

Delighted to share our latest review on 3D multi-omics tumor atlases. A major @theNCI #HTAN team work w/ @deniswirtz @AshleyKiemen @StimulatedRaman @SStevenWang, kudos to my phenomenal postdoc @Miao__Liu and co-contributors Jorge, Andre, & Xiaolong, on this team work! 🥰

@DrChoueiri @QingZhangLab @HHammersMD @EricSingerNow @montypal @tompowles1 @DrRanaMcKay @arihakimi @BradMcG04 @MikeSerzanMD @bergsa83 @advocatekidneys Great to have the virtual option 🎊

@KCRS26 is shaping up to be another fantastic meeting for the #kidneycancer community. Great science, great conversations, and great people! Hope to see many of you in Boston on July 23–24, or online if you can’t make the trip. #KCRS26 will bring together leaders in kidney cancer research, clinical care, advocacy, industry, and the patient community. In-person attendance is limited due to space constraints; however, virtual registration is free and open to all. Register: bit.ly/KCRS26Registra… #KidneyCancer @kidneycan

#PROTEUS trial: Neoadjuvant apalutamide and androgen deprivation therapy in high-risk localized #ProstateCancer. Mary-Ellen Taplin, MD @DanaFarber joins @TDorffOnc @cityofhope to discuss the results. Pathologic complete response of five millimeters or less of residual tumor occurred in 9% of the apalutamide arm vs 1% with placebo; favorable residual cancer burden was achieved in 30% vs 11%, with an odds ratio of 3.3. The study showed that metastasis-free survival favored apalutamide with a hazard ratio of 0.8, and patients receiving apalutamide required 30% less postoperative radiation. #WatchNow on UroToday > bit.ly/3RCNnhX #ASCO26

Andrew Lane, MD, PhD, recently assumed the role of Chief, Division of Hematologic Neoplasia. We look forward to the continued growth and success of the division under his leadership. Please join us in congratulating him on this new role.

@FaltasLab @BladderCancerUS @BCAN_Research @WeillCornell @Cornell @WCMGUcancer @WCMDeptofMed @WCMEnglanderIPM Happy birthday mate 🎉🎊

Today, on my birthday, I am overwhelmed with gratitude for my family, friends, colleagues and the privilege of doing science and caring for patients. One of the best gifts I received today was seeing the fruits of mentorship: not one, but TWO members of the Faltas Lab, Rahul Singh PhD. and Jaekwon Kim MD, PhD, received $100K Young Investigator Awards. Congratulations, Rahul and Jaekwon, on your hard work, persistence, and success. Proud and grateful to be part of your journey! It took us a few tries to spell out YIA, but we managed in the end :) #TeamScience #Mentorship

This #ClinicalTrialsDay, we’re honored to share Mercedes’ story. “When I heard clinical trial, I got very excited,” she says. “I felt like this could be something that not only helps me, but helps so many others.”

We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school. It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases. The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well. We are looking for someone to start ASAP! More information here: postdocs.yale.edu/posts/2026-01-… Please help to spread the word and RT! @DrChoueiri @VanAllenLab @tompowles1 @YaleCancer @YaleMed @SmilowCancer @kidneycan @OncoAlert @OncLive @KidneyCancer @A_P_S_A @cure_today @yalepathology @Yale_Urology @DrYukselUrun @MarkDSiegel1 @OncBrothers @DrKarineTawagi

LBA1/Plenary #ASCO26: PROTEUS trial Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage ! @DanaFarber @DanaFarber_GU @ASCO @OncoAlert

Congrats @charlesrudin well deserved 👏🏼👏🏼👏🏼👏🏼

Excited to share our @natgenet.nature.com study showing that epigenetically rewired transposable elements control AML leukemia stem cell properties and patient outcome. Grateful to the team & collaborators. nature.com/articles/s4158…

It took us a while to convince our clinical colleagues but very happy to see science converted to trial on this one. Bring home the win for PCa patients 🤞🏼👏🏼🤞🏼👏🏼

MEVPRO-3 trial: Testing EZH2 inhibition in first-line metastatic hormone-sensitive #ProstateCancer. @neerajaiims @huntsmancancer joins @TDorffOnc @cityofhope to discuss this phase III trial testing ADT + enzalutamide vs ADT + enzalutamide + the EZH2 inhibitor mevrometostat, aiming to keep tumors dependent on AR signaling. #WatchNow on UroToday > bit.ly/4swwBOB #mHSPC

A huge win for @Roche roche.com/about/leadersh…

What a start to @CPDR_Labs Annual Retreat 2026 with ⁦@RongFan8⁩ as our morning keynote speaker

Two great clinicians doing awesome work.

4-Abstract 5004: A-DREAM In mHSPC, continuous ADT remains the standard, but can we safely de-escalate in exceptional responders? Our very own @AtishChoudhury from @DanaFarber will present this phase 2 trial at #ASCO26, evaluating ADT interruption in patients with deep responses to androgen receptor pathway inhibitors. @DanaFarber_GU @ASCO @OncoAlert